Aclaris Therapeutics Stock In The News
| ACRS Stock | USD 1.17 0.05 4.10% |
The tone or emotional content of news articles related to Aclaris Therapeutics can affect its prices. Positive news sentiment can lead to an increase in demand for Aclaris Therapeutics' stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Aclaris Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Aclaris Therapeutics. The specific impact of Aclaris Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Aclaris Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Aclaris Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Aclaris Therapeutics Backtesting and Aclaris Therapeutics Hype Analysis. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.
Aclaris |
Aclaris Therapeutics Today Top News and Investor Outlook
Aclaris Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Aclaris and other traded companies coverage. We help investors stay connected with Aclaris headlines for the 25th of April to make an informed investment decision based on correlating the impacts of news items on Aclaris Stock performance. Please note that trading solely based on the Aclaris Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.Aclaris Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Aclaris earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Aclaris Therapeutics that are available to investors today. That information is available publicly through Aclaris media outlets and privately through word of mouth or via Aclaris internal channels. However, regardless of the origin, that massive amount of Aclaris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aclaris Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aclaris Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aclaris Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aclaris Therapeutics alpha.
Aclaris Largest EPS Surprises
Earnings surprises can significantly impact Aclaris Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-02-25 | 2020-12-31 | -0.27 | -0.3 | -0.03 | 11 | ||
2022-08-03 | 2022-06-30 | -0.36 | -0.31 | 0.05 | 13 | ||
2020-11-04 | 2020-09-30 | -0.3 | -0.25 | 0.05 | 16 | ||
2020-05-07 | 2020-03-31 | -0.32 | -0.37 | -0.05 | 15 | ||
2016-03-23 | 2015-12-31 | -0.33 | -0.28 | 0.05 | 15 | ||
2021-08-05 | 2021-06-30 | -0.28 | -0.34 | -0.06 | 21 |
Aclaris Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Aclaris Therapeutics Stock. The global stock market is bearish. About 60% of major world exchanges and indexes are down. See today's market update for more information.
1st of April 2024
Disposition of 9467 shares by Neal Walker of Aclaris Therapeutics subject to Rule 16b-3 at news.google.com
28th of March 2024
ACLARIS THERAPEUTICS DL 1 Revenue Breakdown MUN8AT TradingView - TradingView at news.google.com
22nd of March 2024
Will Aclaris Therapeutics Inc Trail the Rest of the Stocks in the Healthcare Sector - Inve... at news.google.com
13th of March 2024
Aclaris Therapeutics, Inc. Given Consensus Recommendation of Hold by Brokerages - MarketBe... at news.google.com
7th of March 2024
Disposition of 427 shares by Kevin Balthaser of Aclaris Therapeutics at 1.24 subject to Ru... at simplywall.st
4th of March 2024
Is Aclaris Therapeutics Outperforming Other Medical Stocks This Year at finance.yahoo.com
1st of March 2024
Aclaris Therapeutics Full Year 2023 Earnings Beats Expectations at finance.yahoo.com
15th of February 2024
Will Aclaris Therapeutics Report Negative Q4 Earnings What You Should Know at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aclaris Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aclaris Therapeutics' short interest history, or implied volatility extrapolated from Aclaris Therapeutics options trading.
Check out Aclaris Therapeutics Backtesting and Aclaris Therapeutics Hype Analysis. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.